amyotrophic lateral sclerosis

Showing 4 posts of 4 posts found.


FDA knocks back Biohaven’s ALS drug over manufacturing concerns

July 22, 2019
Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …


Astellas and Cytokinetics’ reldesemtiv falls short at Phase 2 in ALS

May 7, 2019
Manufacturing and Production, Sales and Marketing Astellas, als, amyotrophic lateral sclerosis, cytokinetics, pharma

Cytokinetics has announced at the American Academy of Neurology (AAN) that its fast skeletal muscle troponin activator (FSTA) reldesemtiv fell …


Aquinnah Pharmaceuticals receives $3.4 million grant to advance ALS therapies

June 21, 2018
Research and Development, Sales and Marketing Aquinnah Pharmaceuticals, als, amyotrophic lateral sclerosis, pharma

Aquinnah Pharmaceuticals has announced that it has been awarded a $3.4 million grant from the National Institute of Neurological Disorders …

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

Latest content